Translational study shows that multiple immunological biomarkers predict the clinical activity of PDS0101 combination therapy PDS01ADC reprograms ...

As global markets navigate through a period of volatility, with concerns over elevated valuations and geopolitical tensions, investors are increasingly turning their attention to Asia's dividend ...

Moderna integrates extensive research and development with both in-house and partner manufacturing to rapidly develop and ...

Recent social media images of Russian President Vladimir Putin's hand, appearing swollen with bulging veins, have fueled ...

At a recent lunch in Melbourne, two dozen luminaries exchanged war stories about their two decades-plus involvement in the ...

Should you buy Nvidia stock hand over fist before Nov. 19? If you think the company will trounce Wall Street's earnings ...

How Ottawa responds through its fiscal strategy will determine whether Canada can navigate this new geopolitical and economic ...

As of Monday, November 10, Molecular Partners AG’s MOLN share price has dipped by 14.98%, which has investors questioning if ...

As of Monday, November 10, Vera Therapeutics, Inc.’s VERA share price has surged by 10.81%, which has investors questioning ...

Access to ERS Genomics’ foundational CRISPR/Cas9 patent portfolio expands our genetic engineering toolkit and strengthens our ability to speed up and optimize strain development across Dyadic’s ...

GENFIT enters research collaboration with EVerZom to advance exosome-based regenerative technology in ACLF: Lille, France Tuesday, November 11, 2025, 10:00 Hrs [IST] GENFIT, a bio ...

ERS Genomics Limited ('ERS'), the CRISPR licensing company, and Dyadic Applied BioSolutions, a global biotechnology company producing precision-engineered ...